Efficacy of a Modified Live Virus Vaccine against Porcine Reproductive and Respiratory Syndrome Virus 1 (PRRSV-1) Administered to 1-Day-Old Piglets in Front of Heterologous PRRSV-1 Challenge
Heinrich Kreutzmann,
Sophie Dürlinger,
Christian Knecht,
Michaela Koch,
Marta Cabana,
Gerard Torrent,
Mònica Balasch,
Lucas P. Taylor,
Gyula Balka,
Wilhelm Gerner,
Andrea Ladinig
Affiliations
Heinrich Kreutzmann
University Clinic for Swine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Sophie Dürlinger
University Clinic for Swine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Christian Knecht
University Clinic for Swine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Michaela Koch
University Clinic for Swine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Marta Cabana
Zoetis Manufacturing and Research Spain S.L., Ctra. Camprodon s/n Finca La Riba, 17813 Girona, Spain
Gerard Torrent
Zoetis Manufacturing and Research Spain S.L., Ctra. Camprodon s/n Finca La Riba, 17813 Girona, Spain
Mònica Balasch
Zoetis Manufacturing and Research Spain S.L., Ctra. Camprodon s/n Finca La Riba, 17813 Girona, Spain
Lucas P. Taylor
Global Development & Operations, Zoetis, Kalamazoo, MI 49007, USA
Gyula Balka
Department of Pathology, University of Veterinary Medicine, 1078 Budapest, Hungary
Wilhelm Gerner
Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Andrea Ladinig
University Clinic for Swine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
PRRSV is one of the most important viruses in the global swine industry and is often controlled by the use of modified live virus (MLV) vaccines. This study assessed the impact of a PRRSV-1 MLV vaccine applied to 1-day-old piglets challenged on day 28 of life with a PRRSV-1 field isolate (AUT15-33). Twenty-one piglets were vaccinated within 24 h of birth (T02), whereas 20 piglets were left unvaccinated (T01). Necropsy was performed two weeks post-challenge. Comparing the two groups, T02 piglets showed significantly higher (p = 0.017) average daily weight gain. In addition, significantly lower (p p p = 0.012 and p < 0.0001, respectively) between the two groups. Hence, this MLV vaccine administered to 1-day-old piglets was able to protect piglets against PRRSV infection at weaning.
